Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
Deniaud-Alexandre E, Touboul E, Lerouge D, Grahek D, Foulquier JN, Petegnief Y, Grès B, El Balaa H, Keraudy K, Kerrou K, Montravers F, Milleron B, Lebeau B, Talbot JN. Deniaud-Alexandre E, et al. Among authors: kerrou k. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1432-41. doi: 10.1016/j.ijrobp.2005.05.016. Epub 2005 Aug 25. Int J Radiat Oncol Biol Phys. 2005. PMID: 16125870
Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma.
Moureau-Zabotto L, Touboul E, Lerouge D, Deniaud-Alexandre E, Grahek D, Foulquier JN, Petegnief Y, Grès B, El Balaa H, Kerrou K, Montravers F, Keraudy K, Tiret E, Gendre JP, Grange JD, Houry S, Talbot JN. Moureau-Zabotto L, et al. Among authors: kerrou k. Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):340-5. doi: 10.1016/j.ijrobp.2005.02.039. Int J Radiat Oncol Biol Phys. 2005. PMID: 16168829
Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Kerbrat P, Dupré PF, Bachelot T, Gabelle P, Giard S, Coeffic D, Bougnoux P, Prevost JB, Paintaud G, Thibault G, Hernandez J, Coudert M, Arnould L, Berriolo-Riedinger A. Coudert B, et al. Among authors: kerrou k. Lancet Oncol. 2014 Dec;15(13):1493-1502. doi: 10.1016/S1470-2045(14)70475-9. Epub 2014 Oct 30. Lancet Oncol. 2014. PMID: 25456368 Clinical Trial.
Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study.
Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Du FL, Dupré PF, Bachelot T, Gabelle P, Chauvet MP, Coeffic D, Barbe C, Prevost JB, Paintaud G, Thibault G, Ferhat A, Dupin J, Berriolo-Riedinger A, Arnould L. Coudert B, et al. Among authors: kerrou k. EClinicalMedicine. 2020 Nov 4;28:100566. doi: 10.1016/j.eclinm.2020.100566. eCollection 2020 Nov. EClinicalMedicine. 2020. PMID: 33205032 Free PMC article.
Sentinel lymph node biopsy in cervix and corpus uteri cancers.
Lelievre L, Camatte S, Le Frere-belda MA, Kerrou K, Froissart M, Taurelle R, Vilde F, Lecuru F. Lelievre L, et al. Among authors: kerrou k. Int J Gynecol Cancer. 2004 Mar-Apr;14(2):271-8. doi: 10.1111/j.1048-891X.2004.014210.x. Int J Gynecol Cancer. 2004. PMID: 15086726 No abstract available.
Mpox Hepatic and Pulmonary Lesions in HIV/Hepatitis B Virus Co-Infected Patient, France.
Calin R, Périllaud-Dubois C, Marot S, Kerrou K, Peytavin G, Bachir M, Kirch AL, Lassel L, Fallet V, Gozlan J, Pain JB, Senet P, Ferraris O, Bine S, Hubert M, Schwartz O, Morand-Joubert L, Pialoux G. Calin R, et al. Among authors: kerrou k. Emerg Infect Dis. 2024 Nov;30(11):2445-2447. doi: 10.3201/eid3011.241331. Emerg Infect Dis. 2024. PMID: 39447209 Free PMC article.
18F-Fluorocholine-Positron Emission Tomography/Computerized Tomography (FCH PET/CT) Imaging for Detecting Abnormal Parathyroid Glands: Indication, Practice, Interpretation and Diagnostic Performance.
Noskovicova L, Balogova S, Aveline C, Tassart M, Zhang-Yin J, Kerrou K, Jaksic I, Montravers F, Talbot JN. Noskovicova L, et al. Among authors: kerrou k. Semin Nucl Med. 2024 Nov;54(6):875-895. doi: 10.1053/j.semnuclmed.2024.08.002. Epub 2024 Sep 20. Semin Nucl Med. 2024. PMID: 39306520
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Pérez-García JM, Cortés J, Ruiz-Borrego M, Colleoni M, Stradella A, Bermejo B, Dalenc F, Escrivá-de-Romaní S, Calvo Martínez L, Ribelles N, Marmé F, Cortés A, Albacar C, Gebhart G, Prat A, Kerrou K, Schmid P, Braga S, Di Cosimo S, Gion M, Antonarelli G, Popa C, Szostak E, Alcalá-López D, Gener P, Rodríguez-Morató J, Mina L, Sampayo-Cordero M, Llombart-Cussac A; PHERGain Trial Investigators. Pérez-García JM, et al. Among authors: kerrou k. Lancet. 2024 Apr 27;403(10437):1649-1659. doi: 10.1016/S0140-6736(24)00054-0. Epub 2024 Apr 3. Lancet. 2024. PMID: 38582092 Clinical Trial.
124 results